For patients with MET exon 14 skipping mutations NSCLC, TKIs, such as capmatinib and tepotinib, received recent FDA approval, while for MET overexpression and amplification, no targeted treatment is currently approved [54]. Here, MET is linked to non-small cell lung carcinoma.